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The future of positron emission tomography/computed
tomography imaging of the heart
Abstract
Metabolic cardiac imaging with [18F]-fluorodeoxyglucose (FDG) and positron emission tomography
(PET) has been established as the diagnostic and prognostic gold standard. This is usually combined
with a perfusion scan, as the classical diagnostic finding is the so-called flow-metabolism mismatch
(low flow, preserved FDG uptake). Hybrid PET/computed tomography (CT) and single photon emission
computed tomography (SPECT)/CT scanners add a new dimension to non invasive diagnostic
procedures, as they allow simultaneous assessment of function (metabolism or perfusion) and coronary
anatomy. Hybrid imaging can integrate metabolic FDG information with CT-visualized anatomy, thus
providing a new approach for diagnosing dysfunctional but viable myocardium by directly visualizing
information on viability in segments subtended by severely stenosed/occluded coronary vessels.
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Metabolic cardiac imaging with [18F]-fluorodeoxyglucose (FDG) and positron emission tomography
(PET) has been established as the diagnostic and prognostic gold standard. This is usually combined with
a perfusion scan, as the classical diagnostic finding is the so-called flow–metabolism mismatch (low
flow, preserved FDG uptake). Hybrid PET/computed tomography (CT) and single photon emission
computed tomography (SPECT)/CT scanners add a new dimension to non invasive diagnostic
procedures, as they allow simultaneous assessment of function (metabolism or perfusion) and
coronary anatomy. Hybrid imaging can integrate metabolic FDG information with CT-visualized
anatomy, thus providing a new approach for diagnosing dysfunctional but viable myocardium by
directly visualizing information on viability in segments subtended by severely stenosed/occluded
coronary vessels.Heart Metab. 2007;34:1–4.Introduction
Positron emission tomography (PET) represents the
most advanced technique in nuclear medicine and
is widely used, not only for research, but also in the
clinical setting for patients with a large diversity of
cardiac diseases. PET allows non invasive functional
assessment of myocardial perfusion, metabolism,
innervation, and receptor density and can provide
quantitative data. At present, PET is the most accurate
method for the quantitative measurement of myo-
cardial perfusion in cardiology. In addition, it is the
‘gold standard’ for the assessment of dysfunctional
but viable (hibernating) myocardium. Despite this
impressive proof of excellence for clinical use, PET
has not been in wide use for long. Only recently has
the widespread use of PET and PET/computed tomo-
graphy (CT) in oncology helped to overcome one ofHeart Metab. 2007; 34:1–4the most important limitations of PET technologies –
its limited availability.
Diagnostic conventional coronary
angiography – the past
Conventional coronary angiography has been the only
accepted ‘gold standard‘ method for clinical imaging of
coronary artery disease (CAD) over past decades.
Despite its cost, inconvenience to patients, and
small but distinct procedure-related morbidity (1.5%)
and mortality (0.15%), in 2002, for example, about
2 million conventional coronary angiography pro-
cedures were performed in Europe [1]. As a percuta-
neous coronary intervention was performed only in
one-third of these procedures, coronary angiography is
mostly used as purely diagnostic tool. The associated
economic burden and the inconvenience to patients1
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Philipp A. Kaufmannhave prompted an intensive search for alternative, non
invasive means of coronary artery imaging [2].
Coronary angiography by computed
tomography – the present challenge
Recent advances in CT using multislice CT (MSCT) with
64 slices [3] and dual-source CT (DSCT) [4] now make
it possible to obtain, non invasively, excellent quality
images of coronary arteries. The negative predictive
value to exclude CAD approaches 100%, severely
challenging the role of coronary angiography as a
purely diagnostic tool. The accuracy of coronary angio-
graphy is severely hampered by a significant variability
(up to 50%), both within and between observers, in
defining the anatomic relevance of stenoses [5,6], as
underlined by a poor correlation with postmortem
coronary anatomy [7,8]. In addition, angiographic
findings are not able to predict the physiologic
relevance of a coronary stenosis [6,9–12]. Therefore,
it has become the clinical standard to require proof of
ischemia by a non invasive test before considering
revascularization procedures [13,14]. This limitation
also applies to computed tomography angiography, as
any assessment of coronary luminology by means of a
purely morpho-anatomical method must remain poor
at predicting the functional relevance of a stenosis [10].
Hybrid imaging – the future
An accurate, non invasive technique for the evalu-
ation of CAD should provide complementary infor-
mation on coronary anatomy and the severity of theFigure 1. The arrowheads on the right image denote a lateral i
and green area), indicating lack of viability in the territory subte
occluded stent (LCX-stent).
2pathophysiologic lesion. Currently, the integration of
functional and morphological information is per-
formed by mentally combining the findings obtained
by coronary angiography with those from myocardial
perfusion imaging (MPI). Unfortunately, the planar
nature of the coronary angiography projections and
the axial slice-by-slice display of cardiac MPI render a
subjective integration difficult, leading to inaccurate
allocation of the coronary lesion to its subtended
myocardial territory. There have been several
attempts to fuse conventional coronary angiography
with MPI [15–17]. This approach does not allow non
invasive preplanning of the intervention, as infor-
mation on the coronary anatomy is obtained only
during conventional coronary angiography. In
addition, the time-consuming process of fusing cor-
onary angiography with MPI is not helpful in rapid
decision-making during a current intervention. Con-
sequently, this approach has not been adopted into
daily clinical routine. Ideally, the complementary
information should be obtained completely non inva-
sively, permitting proper planning of the elective
intervention.
We have recently shown that combination of MPI
with multislice CTA is a feasible and interesting new
approach for non invasive complementary morpho-
anatomical and functional assessment of CAD
[18,19], providing useful information for clinical
decision-making [20]. These very encouraging pre-
liminary data suggest that hybrid imaging has the
potential to be integrated into clinical practice, even-
tually leading to a reduction in the frequency or
overuse of angioplasty and stent placement, a keynfarction without uptake of [18F]-fluorodesoxyglucose (blue
nded by the stented left circumflex coronary artery with an
Heart Metab. 2007; 34:1–4
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Occasionally, in patients in whom the lesion anatomy
is unsuitable for angioplasty, bypass surgery may be
considered directly, without the need for further pre-
operative diagnostic coronary angiography [21].Future role of positron emission tomography/
computed tomography for the assessment
of viability
A mismatch between decreased flow and preserved
uptake of [18F]-fluorodeoxyglucose (FDG) represents
the classical finding diagnostic for hibernating myo-
cardium, as established 20 years ago in the seminal
work by Tillisch and coworkers [22]. Although, at first,
hibernating myocardium was considered to have
reduced resting blood flow, newer data have demon-
strated that patients frequently have normal resting
flow, whereas flow reserve is reduced. To improve the
description and understanding of these two situations,
the term ‘chronic and repetitive stunning’ was sug-
gested for left ventricular dysfunction in the presence
of normal resting flow, the term ‘hibernation’ remain-
ing reserved for the situation of chronic left ventricular
dysfunction with reduced resting flow. Current debate
now suggests that chronic stunning and hibernation
may represent two ends of the spectrum of chronic
ischemia. The real issue in the clinical management
of hibernation remains the prediction of improvement
in function, but also encompasses prognosis after
revascularization.
Several techniques are used for viability testing,
including nuclear imaging (PET or SPECT), dobuta-
mine stress echocardiography, and magnetic reson-
ance imaging. Most clinical experience has been
gained with nuclear techniques, which rely upon
assessment of perfusion, cell integrity, and metab-
olism, as opposed to dobutamine testing, which relies
upon assessment of contractile reserve. Pooled data
have demonstrated that nuclear imaging is more sen-
sitive for the detection of viable myocardium, particu-
larly in severely depressed left ventricular function.
This may be attributable to the fact that contractile
reserve may no longer be preserved (ischemic damage
of the contractile apparatus), whereas other markers of
viability, metabolism, and cell membrane integrity
may still be found. The greater sensitivity of FDG
scanning seems to be of clinical importance, as it
has been clearly shown that patients with viable
tissue, who will not undergo revascularization, have
an unfavorable outcome compared with both those
who undergo revascularization and those without
viable tissue. Patients with a very small amount of
viable tissue, who did not undergo revascularization
because the extent of their left ventricular function
was estimated to be too small to permit improvedHeart Metab. 2007; 34:1–4ventricular function, had the greatest annual mortality
and worst outcome over 8 years of follow-up [23]. As
most of these patients died from sudden cardiac death,
hibernating myocardium seems to be a dangerous
substrate of arrhythmic focus. Viability testing could
be used in the future to identify those patients who
would benefit most from the expensive procedure of
insertion of an implantable cardioverter-defibrillator.
This may be best achieved by using hybrid scanning of
FDG PET with CT angiography (Figure 1). This tech-
nique offers correct assignment of viable and dysfunc-
tional myocardial segments to the territory of the
occluded artery, allowing correct decision making
with regard to revascularization of the cardioverter-
defibrillator implant, without need for perfusion
scanning.REFERENCES
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